Optimer's fidaxomicin better than vancomycin in clostridium difficile Phase III study
This article was originally published in Scrip
Optimer Pharmaceuticals' narrow-spectrum antibiotic, fidaxomicin, has met its primary endpoint in a Phase III non-inferiority study, which pitched it against vancomycin for the treatment of Clostridium difficile infection. Further results of the study were presented at this week's annual European Congress of Clinical Microbiology and Infectious Diseases meeting in Helsinki; top-line results were released last November.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.